Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.48 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | NRP1 | O14786 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | GRB2 | P62993 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30811217 | 0.97 | OPRM1 (0.48) | OPRM1OPRK1F2CXCR4GRB2 | |
| SCHEMBL24485494 | 0.91 | GRB2 (0.49) | OPRM1OPRK1F2NRP1GRB2 | |
| SCHEMBL32690494 | 0.90 | NRP1 (0.46) | OPRM1OPRK1NTSR2NTSR1F2 | |
| SCHEMBL29906667 | 0.89 | NRP1 (0.52) | OPRM1OPRK1NTSR2NTSR1F2 | |
| SCHEMBL29802056 | 0.89 | OPRK1 (0.46) | OPRM1OPRK1 | |
| SCHEMBL31034448 | 0.89 | NRP1 (0.46) | OPRM1OPRK1NTSR2NTSR1SORT1 | |
| SCHEMBL24485493 | 0.88 | F2 (0.49) | OPRM1OPRK1F2NRP1CXCR4 | |
| SCHEMBL30811140 | 0.87 | NMUR2 (0.49) | OPRM1OPRK1F2NRP1CXCR4 | |
| SCHEMBL31099288 | 0.87 | F2 (0.54) | OPRM1OPRK1NTSR2NTSR1SORT1 | |
| SCHEMBL29607267 | 0.87 | F2 (0.54) | OPRM1OPRK1NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | OPRM1 899/4885OPRK1 1491/4885NTSR2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.